Treatment of early-stage HER2+ breast cancer - An evolving field

ecancermedicalscience

Volumn 9, Issue , 2015, Pages

  Ferreira, Arlindo R ^a,b   Saini, Kamal S ^c   Metzger Filho, Otto ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF LISBON   (Portugal)

^c JULES BORDET INSTITUTE   (Belgium)

Author keywords

Adjuvant therapy; Antibodies; Breast neoplasm; Humanised; Monoclonal; Neoadjuvant therapy; Trastuzumab

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; PERTUZUMAB; PLACEBO; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ACUTE LEUKEMIA; ADJUVANT THERAPY; ANEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER THERAPY; CARDIOTOXICITY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; LEUKOPENIA; LOADING DRUG DOSE; MOTOR NEUROPATHY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; REVIEW; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84935008797     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2015.523     Document Type: Review

References (56)

1. Owens MA, Horten BC and Da Silva MM (2004) HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues Clin Breast Cancer 5(1) 63-9 DOI: 10.3816/CBC.2004.n.011 PMID: 15140287
2. Romond EH et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353(16) 1673-84 DOI: 10.1056/NEJMoa052122 PMID: 16236738
3. Piccart-Gebhart MJ et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353(16) 1659-72 DOI: 10.1056/NEJMoa052306 PMID: 16236737
4. Slamon D et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365(14) 1273-83 DOI: 10.1056/NEJ-Moa0910383 PMID: 21991949 PMCID: 3268553
5. Perez EA et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831 J Clin Oncol 32(33) 3744-52 DOI: 10.1200/JCO.2014.55.5730 PMID: 25332249 PMCID: 4226805
6. Joensuu H et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354(8) 809-20 DOI: 10.1056/NEJMoa053028 PMID: 16495393
7. Joensuu H et al (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial J Clin Oncol 27(34) 5685-92 DOI: 10.1200/JCO.2008.21.4577 PMID: 19884557
8. Moja L et al (2012) Trastuzumab containing regimens for early breast cancer Cochrane Database Syst Rev 4 Cd006243 DOI: 10.1002/14651858.CD006243.pub2 PMID: 22513938
9. Tolaney SM et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer N Engl J Med 372(2) 134-41 DOI: 10.1056/NEJMoa1406281 PMID: 25564897 PMCID: 4313867
10. Campiglio M et al (2013) Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study Breast Cancer Res Treat 141(1) 101-10 DOI: 10.1007/s10549-013-2658-z PMID: 23942848 PMCID: 3758836
11. Tripathy D et al (2013) First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER Oncologist 18(5) 501-10 DOI: 10.1634/theoncologist.2012-0414 PMID: 23652380 PMCID: 3662840
12. Vaz-Luis I et al (2014) Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study J Clin Oncol 32(9) 927-34 DOI: 10.1200/JCO.2013.51.1261 PMID: 24516021 PMCID: 3948095
13. Adamo V et al (2014) The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population Oncology 86(1) 16-21 DOI: 10.1159/000353450
14. Mauri D, Pavlidis N and Ioannidis JPA (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis J Natl Cancer Inst 97(3) 188-94 DOI: 10.1093/jnci/dji021 PMID: 15687361
15. Cortazar P et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384(9938) 164-72 DOI: 10.1016/S0140-6736(13)62422-8 PMID: 24529560
16. Buzdar AU et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23(16) 3676-85 DOI: 10.1200/JCO.2005.07.032 PMID: 15738535
17. Buzdar AU et al (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen Clin Cancer Res 13(1) 228-33 DOI: 10.1158/1078-0432.CCR-06-1345 PMID: 17200359
18. Gianni L et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet 375(9712) 377-84 DOI: 10.1016/S0140-6736(09)61964-4 PMID: 20113825
19. Gianni L et al (2014) Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet Oncol 15(6) 640-7 DOI: 10.1016/S1470-2045(14)70080-4 PMID: 24657003
20. Untch M et al (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study J Clin Oncol 28(12) 2024-31 DOI: 10.1200/JCO.2009.23.8451 PMID: 20308670
21. Untch M et al (2012) Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial Lancet Oncol 13(2) 135-44 DOI: 10.1016/S1470-2045(11)70397-7 PMID: 22257523
22. Guarneri V et al (2012) Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB Study J Clinical Oncol 30(16) 1989-95 DOI: 10.1200/JCO.2011.39.0823
23. Baselga J et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet 379(9816) 633-40 DOI: 10.1016/S0140-6736(11)61847-3 PMID: 22257673
24. Piccart-Gebhart MJ et al (2014) First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC) ASCO Annual Meeting Proceedings
25. Gianni L et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13(1) 25-32 DOI: 10.1016/S1470-2045(11)70336-9
26. Pivot X et al (2013) 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial Lancet Oncol 14(8) 741-8 DOI: 10.1016/S1470-2045(13)70225-0 PMID: 23764181
27. Goldhirsch A et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Lancet 382(9897) 1021-8 DOI: 10.1016/S0140-6736(13)61094-6 PMID: 23871490
28. Perez EA et al (2008) Cardiac safety snalysis of doxorubicin and cyclophosphamide Followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial J Clin Oncol 26(8) 1231-8 DOI: 10.1200/JCO.2007.13.5467 PMID: 18250349 PMCID: 4048960
29. Tan-Chiu E et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 J Clin Oncol 23(31) 7811-9 DOI: 10.1200/JCO.2005.02.4091 PMID: 16258083
30. Procter M et al (2010) Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial J Clin Oncol 28(21) 3422-8 DOI: 10.1200/JCO.2009.26.0463 PMID: 20530280
31. Burstein HJ et al (2012) Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol 30(18) 2179-82 DOI: 10.1200/JCO.2012.42.0695 PMID: 22614986
32. Perez EA et al (2011) Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer J Clin Oncol 29(34) 4491-7 DOI: 10.1200/JCO.2011.36.7045 PMID: 22042958 PMCID: 3236650
33. Buzdar AU et al (2013) Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial Lancet Oncol 14(13) 1317-25 DOI: 10.1016/S1470-2045(13)70502-3 PMID: 24239210 PMCID: 4176878
34. Liberato NL, Marchetti M and Barosi G (2007) Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 25(6) 625-33 DOI: 10.1200/JCO.2006.06.4220 PMID: 17308267
35. Ismael G et al (2012) Subcutaneous versus intravenous administration of (neo) adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial Lancet Oncol 13(9) 869-78 DOI: 10.1016/S1470-2045(12)70329-7 PMID: 22884505
36. Pivot X et al (2013) Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study Lancet Oncol 14(10) 962-70 DOI: 10.1016/S1470-2045(13)70383-8 PMID: 23965225
37. Gebhart G et al (2013) 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO J Nucl Med 54(11) 1862-8 DOI: 10.2967/jnumed.112.119271 PMID: 24092940
38. Dijkers EC et al (2010) Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer Clin Pharmcol Ther 87(5) 586-92 DOI: 10.1038/clpt.2010.12
39. Saini KS et al (2011) Beyond trastuzumab: new treatment options for HER2-positive breast cancer Breast 20 Supplement 3(0) S20-7 DOI: 10.1016/S0960-9776(11)70289-2 PMID: 22015288
40. GlaxoSmithKline ALTTO Trial-Trial Overview 2012 [October 19 2013] available from: http://alttotrials.com/hcp.php
41. Franklin MC et al (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex Cancer Cell 5(4) 317-28 DOI: 10.1016/S1535-6108(04)00083-2 PMID: 15093539
42. Scheuer W et al (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models Cancer Res 69(24) 9330-6 DOI: 10.1158/0008-5472.CAN-08-4597 PMID: 19934333
43. Baselga J et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer New Engl J Med 366(2) 109-19 DOI: 10.1056/NEJMoa1113216
44. Schneeweiss A et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) Ann Oncol 24(9) 2278-84 DOI: 10.1093/annonc/mdt182 PMID: 23704196
45. Lewis Phillips GD et al (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 68(22) 9280-90 DOI: 10.1158/0008-5472.CAN-08-1776 PMID: 19010901
46. Vaz-Luis I et al (2014) Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study J Clinical Oncol 32(20) 2142-50 DOI: 10.1200/JCO.2013.53.1608
47. Gonzalez-Angulo AM et al (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller J Clin Oncol 27(34) 5700-6 DOI: 10.1200/JCO.2009.23.2025 PMID: 19884543 PMCID: 2792998
48. Chia S et al (2008) Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers J Clin Oncol 26(35) 5697-704 DOI: 10.1200/JCO.2007.15.8659 PMID: 19001334
49. Constantinidou A and Smith I (2011) Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer? Breast 20 Supplement 3(0) S158-61 DOI: 10.1016/S0960-9776(11)70316-2 PMID: 22015286
50. Gianni L et al (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Lancet Oncol 12(3) 236-44 DOI: 10.1016/S1470-2045(11)70033-X PMID: 21354370
51. Spielmann M et al (2009) Trastuzumab for patients with axillary node-positive breast cancer: results of the FNCLCC-PACS 04 Trial J Clin Oncol 27(36) 6129-34 DOI: 10.1200/JCO.2009.23.0946 PMID: 19917839
52. Robidoux A et al (2013) Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial Lancet Oncology 14(12) 1183-92 DOI: 10.1016/S1470-2045(13)70411-X
53. Carey L, Berry D and Ollila D (2013) Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer J Clin Oncol 31(15 Suppl) 500
54. Hurvitz S et al (2013) Abstract S1-02: Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+ breast cancer (TRIO-US B07) Cancer Res 73(24 Supplement) S1-2 DOI: 10.1158/0008-5472.SABCS13-S1-02
55. Rimawi MF et al (2013) Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006 J Clin Oncol 31(14) 1726-31 DOI: 10.1200/JCO.2012.44.8027 PMID: 23569315 PMCID: 3641695
56. Holmes FA et al (2011) Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy J Clin Oncol 29 (suppl abstr 506)